Navigation Links
Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
Date:1/15/2008

PHILADELPHIA, Jan. 15 /PRNewswire/ -- Premier Research Group plc (AIM: PRG), the international pharmaceutical services group, announces the appointment of Patrick Melvin as Senior Director, Clinical Trial Management specializing in oncology-related research. In this position, Mr. Melvin will play a leading role in the operations, strategic planning and corporate development of Premier Research's growing portfolio of oncology business.

Over the past nine years, Mr. Melvin managed hematology/oncology programs ranging from Phase I first-in-man studies through pivotal global Phase III programs. His early phase experience included multiple variations of early phase designs, including PK/PD studies, traditional dose-escalating maximum tolerated dose studies, Simon two-stage studies, and adaptive design studies. The later phase studies included extensive global experience in hematology/oncology clinical research including clinical program and client activities in the United States, Western and Eastern Europe, Latin America, and Asia. His responsibilities incorporated consulting with clients on clinical development plans and protocol design for new hematology/oncology studies. Mr. Melvin began his clinical research career as a CRA at a global clinical research organization and, after five years of serving in various monitoring positions, entered project management specializing in hematology and oncology drug development.

"Mr. Melvin is an exceptional addition to our team," said Krista Armstrong, Ph.D., Vice President, Clinical Trial Management. "As we continue to expand our presence within the oncology market, Mr. Melvin's substantial clinical and management expertise will be beneficial in continuing to establish Premier Research as an industry leader."

About Premier Research

Premier Research is a leading solutions-driven CRO leveraging their commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research. Premier Research has 29 offices and operates in more than 30 countries across Europe and North America. They employ a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at a well-established network of dedicated clinical sites.


'/>"/>
SOURCE Premier Research Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
2. Premier Research Appoints Global Head of Human Resources
3. Premier Research Appoints Melissa Jones as Vice President, International Business Development
4. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
7. Association of Clinical Research Organizations (ACRO) Elects New Officers for 2008
8. Biomoda Hires Senior Scientist to Expand Research & Development Effort
9. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
10. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
11. Researchers use magnetism to target cells to animal arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):